What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial

Routine thromboprophylaxis (TP) in newly-diagnosed multiple myeloma (NDMM) patients comprises either aspirin for standard risk patients or low molecular weight heparin for high risk patients. Studies using DOACs in cancer patients include few with myeloma. The aim of this feasibility clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayar, Zara, Czuprynska, Julia, Patel, Jignesh P., Benjamin, Reuben, Roberts, Lara N., Patel, Raj K., Cornelius, Victoria, Arya, Roopen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599493/
https://www.ncbi.nlm.nih.gov/pubmed/31168688
http://dx.doi.org/10.1007/s11239-019-01891-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599493/
https://www.ncbi.nlm.nih.gov/pubmed/31168688
http://dx.doi.org/10.1007/s11239-019-01891-0

Ejemplares similares